Industry association · Belgium · EU Transparency Register 48325781850-28
8
positions filed
in the 326 files tracked
6
legislative files
of 326 tracked
8
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1205 trade and business associations on this site, they rank #238 by legislative files engaged — a count of participation, not a measure of influence.
7.9
declared lobbying FTE
self-declared
€500K+
declared costs / yr (floor)
10
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
Consultative status with World Intellectual Property Organization (WIPO)
Founding Member of International Generic and Biosimilar Medicine Association (IGBA)
Member Federation of European and International Associations Established in Belgium (FAIB)
Founding Member of the European Medicines Verification Organisation (EMVO)
Observer of the Organisation for Economic Co-operation and Development (OECD)
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
Register category
Trade and business associations
Registered as
MEDICINES FOR EUROPE (-)
Head office
BRUSSELS, Belgium
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Work at Medicines for Europe? so we know who speaks for it.
Their record over time
Medicines for Europe filed 8 positions between 6 Mar 2025 and 3 Aug 2026, across 6 of the 326 legislative files tracked here, attaching a full position paper 8 times.
Call for evidence – Circular Economy Act Medicines for Europe response Medicines for Europe, representing generic, biosimilar, and value-added medicines, supports the objectives of the Circular Economy Act to enhance circularity across the single market, while underlining the importance of duly considering the specificities of the strictly regulated pharmaceutical sector and the need to ensure consistency with…
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
Medicines for Europe welcomes the opportunity to contribute to this call for evidence, as the revision of the Public Procurement Directive 2014/24/EU (PPD) provides a framework for the public procurement of medicines (PPM). The off-patent pharmaceutical sector is operating in a highly regulated pricing framework, which does not allow for the adjustment of prices to increasing costs (e.g.
Medicines for Europe welcomes the European Commissions proposal regarding the adoption of the MDR. We support the overall aim of making the regulatory framework simpler, more efficient and more proportionate, while continuing to ensure a high level of patient safety.
Medicines for Europe welcomes the opportunity to comment on the targeted revision of the EU rules for medical devices and in vitro diagnostics. We support a revision that makes the system clearer, more efficient and proportionate, as the current Medical Device Regulation (MDR) has created many challenges for products that combine a medicine and a device leading to delays, uncertainty and additional administrative…
Medicines for Europe, representing generic, biosimilar, and value-added medicines in Europe, welcomes the opportunity to contribute to the call for feedback on the review of the EU Taxonomy Environmental Delegated Act. Please find our submission attached.
Dear Sir/Madam, Enclosed you will find the contribution of the Biosimilar medicines group, a Medicines for Europe sector group to the European Commissions call for feedback on the proposed European Biotech Act I (Health). We remain at disposal should you need any clarification. Kind regards
On behalf of the Biosimilar medicines group, a Medicines for Europe sector group, please find attached our contribution on the future Biotech Act. The Biosimilar Medicines Group represents the leading companies developing, manufacturing and/or marketing biosimilar medicines across Europe. Our members contribute actively to the European biotech ecosystem, including through innovation on processes.
Dear Sir/Madam, Enclosed you will find the contribution of the Biosimilar medicines group, a Medicines for Europe sector group on the EC Call for Evidence for the Biotech Act II (industrial biotech). We remain at disposal should you need any clarification. Kind regards,
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Everything on this page comes from Medicines for Europe’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.
